235 related articles for article (PubMed ID: 25714853)
1. Targeting multiple tyrosine kinase receptors with Dovitinib blocks invasion and the interaction between tumor cells and cancer-associated fibroblasts in breast cancer.
Zang C; Eucker J; Habbel P; Neumann C; Schulz CO; Bangemann N; Kissner L; Riess H; Liu H
Cell Cycle; 2015; 14(8):1291-9. PubMed ID: 25714853
[TBL] [Abstract][Full Text] [Related]
2. Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-α and the NF-κB pathway.
Katanov C; Lerrer S; Liubomirski Y; Leider-Trejo L; Meshel T; Bar J; Feniger-Barish R; Kamer I; Soria-Artzi G; Kahani H; Banerjee D; Ben-Baruch A
Stem Cell Res Ther; 2015 May; 6(1):87. PubMed ID: 25928089
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.
Issa A; Gill JW; Heideman MR; Sahin O; Wiemann S; Dey JH; Hynes NE
Breast Cancer Res; 2013 Jan; 15(1):R8. PubMed ID: 23343422
[TBL] [Abstract][Full Text] [Related]
4. Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.
Chen ZY; Shi M; Peng LX; Wei W; Li XJ; Guo ZX; Li SH; Zhong C; Qian CN; Guo RP
J Transl Med; 2012 Dec; 10():245. PubMed ID: 23228017
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways.
Zervantonakis IK; Poskus MD; Scott AL; Selfors LM; Lin JR; Dillon DA; Pathania S; Sorger PK; Mills GB; Brugge JS
Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16500-16508. PubMed ID: 32601199
[TBL] [Abstract][Full Text] [Related]
6.
Das A; Martinez Santos JL; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
Cancer Invest; 2020 Jul; 38(6):349-355. PubMed ID: 32441531
[No Abstract] [Full Text] [Related]
7. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
[TBL] [Abstract][Full Text] [Related]
8. Cancer-associated fibroblasts promote proliferation of endometrial cancer cells.
Subramaniam KS; Tham ST; Mohamed Z; Woo YL; Mat Adenan NA; Chung I
PLoS One; 2013; 8(7):e68923. PubMed ID: 23922669
[TBL] [Abstract][Full Text] [Related]
9. Rocuronium bromide suppresses esophageal cancer via blocking the secretion of C-X-C motif chemokine ligand 12 from cancer associated fibroblasts.
Li J; Gu X; Wan G; Wang Y; Chen K; Chen Q; Lu C
J Transl Med; 2023 Apr; 21(1):248. PubMed ID: 37029408
[TBL] [Abstract][Full Text] [Related]
10. Oxidized ATM promotes abnormal proliferation of breast CAFs through maintaining intracellular redox homeostasis and activating the PI3K-AKT, MEK-ERK, and Wnt-β-catenin signaling pathways.
Tang S; Hou Y; Zhang H; Tu G; Yang L; Sun Y; Lang L; Tang X; Du YE; Zhou M; Yu T; Xu L; Wen S; Liu C; Liu M
Cell Cycle; 2015; 14(12):1908-24. PubMed ID: 25970706
[TBL] [Abstract][Full Text] [Related]
11. p16INK4A represses breast stromal fibroblasts migration/invasion and their VEGF-A-dependent promotion of angiogenesis through Akt inhibition.
Al-Ansari MM; Hendrayani SF; Tulbah A; Al-Tweigeri T; Shehata AI; Aboussekhra A
Neoplasia; 2012 Dec; 14(12):1269-77. PubMed ID: 23308058
[TBL] [Abstract][Full Text] [Related]
12. Melittin suppresses EGF-induced cell motility and invasion by inhibiting PI3K/Akt/mTOR signaling pathway in breast cancer cells.
Jeong YJ; Choi Y; Shin JM; Cho HJ; Kang JH; Park KK; Choe JY; Bae YS; Han SM; Kim CH; Chang HW; Chang YC
Food Chem Toxicol; 2014 Jun; 68():218-25. PubMed ID: 24675423
[TBL] [Abstract][Full Text] [Related]
13. Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.
Polo ML; Riggio M; May M; Rodríguez MJ; Perrone MC; Stallings-Mann M; Kaen D; Frost M; Goetz M; Boughey J; Lanari C; Radisky D; Novaro V
Oncotarget; 2015 Sep; 6(26):22081-97. PubMed ID: 26098779
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
[TBL] [Abstract][Full Text] [Related]
15. Estrogen promotes progression of hormone-dependent breast cancer through CCL2-CCR2 axis by upregulation of Twist via PI3K/AKT/NF-κB signaling.
Han R; Gu S; Zhang Y; Luo A; Jing X; Zhao L; Zhao X; Zhang L
Sci Rep; 2018 Jun; 8(1):9575. PubMed ID: 29934505
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Evaluation of a Fluorine-18 (
Altine B; Gai Y; Han N; Jiang Y; Ji H; Fang H; Niyonkuru A; Bakari KH; Rajab Arnous MM; Liu Q; Zhang Y; Lan X
Mol Pharm; 2019 Nov; 16(11):4563-4571. PubMed ID: 31553879
[TBL] [Abstract][Full Text] [Related]
17. Melanoma cell-derived factors stimulate hyaluronan synthesis in dermal fibroblasts by upregulating HAS2 through PDGFR-PI3K-AKT and p38 signaling.
Pasonen-Seppänen S; Takabe P; Edward M; Rauhala L; Rilla K; Tammi M; Tammi R
Histochem Cell Biol; 2012 Dec; 138(6):895-911. PubMed ID: 22825838
[TBL] [Abstract][Full Text] [Related]
18. Characterization of gastric cancer-stimulated signaling pathways and function of CTGF in cancer-associated fibroblasts.
Choi KM; Kim B; Lee SM; Han J; Bae HS; Han SB; Lee D; Ham IH; Hur H; Kim E; Kim JY
Cell Commun Signal; 2024 Jan; 22(1):8. PubMed ID: 38167009
[TBL] [Abstract][Full Text] [Related]
19. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
[TBL] [Abstract][Full Text] [Related]
20. CUDC‑907 reverses pathological phenotype of keloid fibroblasts in vitro and in vivo via dual inhibition of PI3K/Akt/mTOR signaling and HDAC2.
Tu T; Huang J; Lin M; Gao Z; Wu X; Zhang W; Zhou G; Wang W; Liu W
Int J Mol Med; 2019 Nov; 44(5):1789-1800. PubMed ID: 31545402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
